Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 5/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KAT7 | O95251 | 2/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.34 |
| ▸ | KAT6B | Q8WYB5 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172751 | 0.86 | KAT7 (0.37) | KLKB1BRD4HDAC1HDAC6HTT | |
| SCHEMBL31172637 | 0.85 | KLKB1 (0.46) | KLKB1BRD4HDAC1HDAC6HTT | |
| SCHEMBL31172689 | 0.85 | KDM4E (0.39) | KLKB1BRD4HDAC1HDAC6HTT | |
| SCHEMBL31172623 | 0.85 | BRD4 (0.36) | KLKB1BRD4HDAC1HDAC6HTT | |
| SCHEMBL31172826 | 0.85 | THRB (0.39) | KLKB1BRD4HDAC1HDAC6HTT | |
| SCHEMBL31172742 | 0.84 | ALDH1A1 (0.35) | KLKB1BRD4HDAC1HDAC6HTT | |
| SCHEMBL31172747 | 0.81 | HTT (0.47) | KLKB1BRD4HDAC1HDAC6HTT | |
| SCHEMBL31172565 | 0.77 | KAT7 (0.40) | KLKB1BRD4HDAC1HDAC6HTT | |
| SCHEMBL31172672 | 0.75 | KAT7 (0.42) | KLKB1HDAC1HDAC6HTTMEN1 | |
| SCHEMBL31172695 | 0.72 | MEN1 (0.43) | KLKB1BRD4HDAC1HDAC6HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | OLEMA PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2024189598-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | KLKB1 1815/4885BRD4 426/4885HDAC1 9/4885 |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | KAT6A, KAT2A, KAT6B | KLKB1 1815/4885BRD4 426/4885HDAC1 9/4885 |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | KLKB1 4177/4885BRD4 358/4885HDAC1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.